Research Analysts Issue Forecasts for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – HC Wainwright lifted their Q1 2025 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Tuesday, February 11th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.55 for the quarter, up from their prior estimate of $0.36. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $2.51 EPS, FY2026 earnings at $4.37 EPS, FY2027 earnings at $6.36 EPS and FY2028 earnings at $7.67 EPS.

A number of other equities research analysts have also commented on CORT. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, Canaccord Genuity Group raised their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $88.25.

Corcept Therapeutics Trading Up 4.9 %

NASDAQ CORT opened at $73.61 on Thursday. The firm has a market cap of $7.71 billion, a P/E ratio of 58.42 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock’s 50-day moving average is $57.45 and its 200-day moving average is $48.88. Corcept Therapeutics has a one year low of $20.84 and a one year high of $73.75.

Insider Activity at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 1,411 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now owns 8,494 shares of the company’s stock, valued at approximately $481,779.68. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,011 shares of company stock valued at $1,479,608. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. M&G PLC bought a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $11,173,000. Synergy Asset Management LLC boosted its stake in shares of Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after acquiring an additional 262,503 shares during the period. Empowered Funds LLC bought a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $1,784,000. Victory Capital Management Inc. boosted its stake in shares of Corcept Therapeutics by 49.2% during the 3rd quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after acquiring an additional 13,787 shares during the period. Finally, State Street Corp boosted its stake in shares of Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock worth $162,871,000 after acquiring an additional 19,893 shares during the period. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.